BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26997151)

  • 1. Computer Aided Drug Design Approaches for Identification of Novel Autotaxin (ATX) Inhibitors.
    Vrontaki E; Melagraki G; Kaffe E; Mavromoustakos T; Kokotos G; Aidinis V; Afantitis A
    Curr Med Chem; 2016; 23(17):1708-24. PubMed ID: 26997151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and therapeutic potential of autotaxin small molecule inhibitors: From bench to advanced clinical trials.
    Matralis AN; Afantitis A; Aidinis V
    Med Res Rev; 2019 May; 39(3):976-1013. PubMed ID: 30462853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autotaxin inhibitors: a patent review.
    Barbayianni E; Magrioti V; Moutevelis-Minakakis P; Kokotos G
    Expert Opin Ther Pat; 2013 Sep; 23(9):1123-32. PubMed ID: 23641951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autotaxin inhibitors: a patent review (2012-2016).
    Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
    Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis, and Preliminary Bioactivity Evaluation of 2,7-Substituted Carbazole Derivatives as Potent Autotaxin Inhibitors and Antitumor Agents†.
    Wang W; Zhao F; Zhao Y; Pan W; Cao P; Wu L; Wang Z; Zhao X; Zhao Y; Wang H
    Anticancer Agents Med Chem; 2019; 19(2):256-264. PubMed ID: 30173652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors.
    Magkrioti C; Kaffe E; Stylianaki EA; Sidahmet C; Melagraki G; Afantitis A; Matralis AN; Aidinis V
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of a pipemidic acid autotaxin inhibitor.
    Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
    J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature.
    Castagna D; Budd DC; Macdonald SJ; Jamieson C; Watson AJ
    J Med Chem; 2016 Jun; 59(12):5604-21. PubMed ID: 26745766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand and structure based virtual screening strategies for hit-finding and optimization of hepatitis C virus (HCV) inhibitors.
    Melagraki G; Afantitis A
    Curr Med Chem; 2011; 18(17):2612-9. PubMed ID: 21568888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.
    Ragle LE; Palanisamy DJ; Joe MJ; Stein RS; Norman DD; Tigyi G; Baker DL; Parrill AL
    Bioorg Med Chem; 2016 Oct; 24(19):4660-4674. PubMed ID: 27544588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.
    Stein AJ; Bain G; Prodanovich P; Santini AM; Darlington J; Stelzer NM; Sidhu RS; Schaub J; Goulet L; Lonergan D; Calderon I; Evans JF; Hutchinson JH
    Mol Pharmacol; 2015 Dec; 88(6):982-92. PubMed ID: 26371182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virtual screening approaches for the identification of non-lipid autotaxin inhibitors.
    Parrill AL; Echols U; Nguyen T; Pham TC; Hoeglund A; Baker DL
    Bioorg Med Chem; 2008 Feb; 16(4):1784-95. PubMed ID: 18036821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of 2,4-dihydropyrano[2,3-c]pyrazole derivatives as autotaxin inhibitors.
    Pantsar T; Singha P; Nevalainen TJ; Koshevoy I; Leppänen J; Poso A; Niskanen JMA; Pasonen-Seppänen S; Savinainen JR; Laitinen T; Laitinen JT
    Eur J Pharm Sci; 2017 Sep; 107():97-111. PubMed ID: 28687529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of novel 2-pyrrolidinone and pyrrolidine derivatives and study of their inhibitory activity against autotaxin enzyme.
    Gerokonstantis DT; Nikolaou A; Magkrioti C; Afantitis A; Aidinis V; Kokotos G; Moutevelis-Minakakis P
    Bioorg Med Chem; 2020 Jan; 28(2):115216. PubMed ID: 31864778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Novel Indole-Based Allosteric Highly Potent ATX Inhibitors with Great
    Lei H; Guo M; Li X; Jia F; Li C; Yang Y; Cao M; Jiang N; Ma E; Zhai X
    J Med Chem; 2020 Jul; 63(13):7326-7346. PubMed ID: 32479084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, docking and biological evaluation of 4-phenyl-thiazole derivatives as autotaxin (ATX) inhibitors.
    Balupuri A; Lee DY; Lee MH; Chae S; Jung E; Kim Y; Ryu J; Kang NS
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4156-4164. PubMed ID: 28743508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An updated patent review of autotaxin inhibitors (2017-present).
    Tan Z; Lei H; Guo M; Chen Y; Zhai X
    Expert Opin Ther Pat; 2021 May; 31(5):421-434. PubMed ID: 33342311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The chemical synthesis of metabolically stabilized 2-OMe-LPA analogues and preliminary studies of their inhibitory activity toward autotaxin.
    Gendaszewska-Darmach E; Laska E; Rytczak P; Okruszek A
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2698-700. PubMed ID: 22460025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe.
    Kawaguchi M; Okabe T; Okudaira S; Nishimasu H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
    ACS Chem Biol; 2013 Aug; 8(8):1713-21. PubMed ID: 23688339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and optimization of tetrahydropyrido[4,3-d]pyrimidine derivatives as novel ATX and EGFR dual inhibitors.
    Jing T; Miao X; Jiang F; Guo M; Xing L; Zhang J; Zuo D; Lei H; Zhai X
    Bioorg Med Chem; 2018 May; 26(8):1784-1796. PubMed ID: 29496411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.